Zacks: ObsEva SA (OBSV) Receives Average Rating of “Strong Buy” from Brokerages

Shares of ObsEva SA (NASDAQ:OBSV) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus target price of $24.00 for the company and are forecasting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also assigned ObsEva SA an industry rank of 122 out of 265 based on the ratings given to its competitors.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research upgraded ObsEva SA from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright assumed coverage on ObsEva SA in a research note on Thursday, June 29th. They set a “buy” rating and a $27.00 price objective for the company. Finally, Credit Suisse Group restated an “outperform” rating and set a $27.00 price objective on shares of ObsEva SA in a research note on Tuesday, April 18th.

Large investors have recently added to or reduced their stakes in the stock. NEA Management Company LLC acquired a new stake in ObsEva SA during the first quarter worth approximately $34,734,000. Sphera Funds Management LTD. acquired a new stake in ObsEva SA during the first quarter worth approximately $2,197,000. UBS Oconnor LLC acquired a new stake in ObsEva SA during the first quarter worth approximately $1,017,000. Citadel Advisors LLC acquired a new stake in ObsEva SA during the first quarter worth approximately $937,000. Finally, Nexthera Capital LP acquired a new stake in ObsEva SA during the first quarter worth approximately $521,000. Institutional investors own 49.24% of the company’s stock.

Shares of ObsEva SA (OBSV) traded up 2.6423% during trading on Wednesday, reaching $8.5501. The company’s stock had a trading volume of 13,215 shares. The company has a 50-day moving average price of $7.31 and a 200-day moving average price of $9.35. The stock’s market cap is $253.35 million. ObsEva SA has a one year low of $5.00 and a one year high of $14.70.

ObsEva SA (NASDAQ:OBSV) last posted its quarterly earnings results on Thursday, May 18th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.17. On average, equities research analysts forecast that ObsEva SA will post ($2.04) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “[[title]]” was reported by [[site]] and is the sole property of of [[site]]. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at [[permalink]].

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Get a free copy of the Zacks research report on ObsEva SA (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com